Retrospective cohort study utilizing COVIREGI-JP to evaluate the efficacy of tocilizumab for severe COVID-19 pneumonia
Not Applicable
- Conditions
- COVID-19
- Registration Number
- JPRN-UMIN000043622
- Lead Sponsor
- ational Center for Global Health and Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 248
Inclusion Criteria
Not provided
Exclusion Criteria
[COVIREGI-JP cohort] 1)Pregnant women 2)Patients administered with any of the below during hospitalization - Sarilumab - Baricitinib
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time until discharge or waiting for discharge (with normal body temperature and respiratory rate, stable oxygen saturation under ambient air or oxygenation of 2 L or less)
- Secondary Outcome Measures
Name Time Method 7-point scale clinical categorization